SAGE Therapeutics (SAGE): Primary Endpoints in Both Phase III PPD Trials Met - Suntrust
Tweet Send to a Friend
SunTrust Robinson Humphrey analyst, Edward Nash, reiterated his Buy rating on shares of Sage Therapeutics (NASDAQ: SAGE) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
